TENX (Tenax Therapeutics) Gross Margin %: 0.00% (As of Mar. 2026)


TENX Tenax Therapeutics Inc TENX
22 GF Score
Price $13.44
! 2 Warning Signs
View Full Analysis

What is Tenax Therapeutics Gross Margin %?

Tenax Therapeutics TENX +4.39% 22 Gross Margin % is 0.00% as of Mar. 2026. GuruFocus rates TENX with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 737 Biotechnology companies, Tenax Therapeutics ranks worse than 135685.07% on this metric.

Gross Margin % is calculated as gross profit divided by its revenue. Tenax Therapeutics's Gross Profit for the three months ended in Mar. 2026 was $0.00 Mil. Tenax Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Tenax Therapeutics's Gross Margin % for the quarter that ended in Mar. 2026 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Tenax Therapeutics's Gross Margin % or its related term are showing as below:


TENX's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.92
* Ranked among companies with meaningful Gross Margin % only.

Tenax Therapeutics had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Tenax Therapeutics was 0.00% per year.


Tenax Therapeutics  (NAS:TENX) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Tenax Therapeutics had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Tenax Therapeutics Gross Margin % Related Terms


Tenax Therapeutics Gross Margin % Historical Data

* Premium members only.

The historical data trend for Tenax Therapeutics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tenax Therapeutics Gross Margin % Chart

Tenax Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Tenax Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TENX vs RZLT, PRLD, NAGE: Gross Margin % Comparison

For the Biotechnology subindustry, Tenax Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tenax Therapeutics Gross Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tenax Therapeutics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Tenax Therapeutics's Gross Margin % falls into.


TENX
22GF Score
Tenax Therapeutics Inc TENX
Gross Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tenax Therapeutics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Tenax Therapeutics's Gross Margin for the fiscal year that ended in Dec. 2025 is calculated as

Gross Margin % (A: Dec. 2025 )=Gross Profit (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

Tenax Therapeutics's Gross Margin for the quarter that ended in Mar. 2026 is calculated as


Gross Margin % (Q: Mar. 2026 )=Gross Profit (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Frequently Asked Questions Learn more about Gross Margin % →
What does a Gross Margin % of 0.00% mean?
Tenax Therapeutics (TENX) has a Gross Margin % of 0.00% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Tenax Therapeutics and its competitors. According to the industry distribution chart, Tenax Therapeutics ranks #999999 out of 737 companies in the Biotechnology industry.
Is Tenax Therapeutics' Gross Margin % too high?
Tenax Therapeutics' current Gross Margin % is 0.00%. Based on the distribution chart, Tenax Therapeutics ranks #999999 out of 737 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tenax Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Tenax Therapeutics' Gross Margin % compare to RZLT and PRLD?
According to the Biotechnology industry distribution chart, Tenax Therapeutics ranks #999999 out of 737 companies for Gross Margin %. This places Tenax Therapeutics in the lower half of its industry. The industry median Gross Margin % is 60.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Tenax Therapeutics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tenax Therapeutics's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenax Therapeutics stock overvalued right now?
Tenax Therapeutics (TENX) has a current Gross Margin % of 0.00%. The current Gross Margin % is 0.00%. Tenax Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Tenax Therapeutics (TENX), the current Gross Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tenax Therapeutics Business Description

Other Exchanges YBO0:Germany
Address 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
22GF Score

Get the complete analysis for TENX

Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.44
Price